Novo Holdings Invests $40M in Evosep

Novo Holdings Invests $72 Million in LanzaTech

August 6, 2019

Biotechnology

Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.

Novo Holdings Invests £50m in Oxford Nanopore Technologies

August 1, 2024

Biotechnology

Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

Novo Holdings Leads €7M Seed Investment in Bactolife

April 20, 2021

Biotechnology

Novo Holdings (via its Novo Seeds team) led a €7 million seed round in Danish biotech Bactolife, committing €5 million to advance the company's pipeline. The funding will support development and scaling of Bactolife's anti-virulence Virulence Inactivating Proteins (VIPs) for animal and human gut health; Novo's Aleks Engel will join Bactolife's board.

Novo Holdings Acquires Majority Stake in Single Use Support

May 15, 2024

Biotechnology

Novo Holdings A/S agreed to acquire an approximately 60% controlling stake in Single Use Support, a Kufstein, Austria-based life science tools company specializing in fluid management, single-use consumables and cold-chain solutions for bioprocessing. The two founders will each retain 10% and Danaher will retain 20%; the investment is intended to support Single Use Support's next phase of global growth, particularly expansion into the US and Asia, and is subject to regulatory approvals.

Avista Capital Partners Invests in eMolecules

March 25, 2021

Healthcare Services

Avista Capital Partners has signed a definitive agreement to invest in eMolecules, a San Diego–based e-procurement and marketplace platform for high-value chemicals and bioreagents used in drug discovery. Financial terms were not disclosed; Avista said the investment will support eMolecules' growth and expansion into additional biopharma and academic customers.

Novo Holdings Invests in Oxford Biomedica plc

May 28, 2019

Biotechnology

Novo Holdings A/S agreed to invest up to £53.5 million in new ordinary shares of Oxford Biomedica plc, taking up to a 10.1% stake. The proceeds will be used to repay an existing Oaktree debt facility in full and to scale Oxford Biomedica's LentiVector platform and proprietary product portfolio.